OncLive TV

MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, American Cancer Society, discusses updated screening guidelines in prostate cancer.

Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

Yadav Sapkota, PhD, clinical research scientist at St. Jude Children’s Research Hospital, discusses the relationship between a genetic variant and the risk of stroke in childhood cancer survivors treated with cranial radiation therapy.

Leslie M. Randall, MD, associate professor, Division of Gynecologic Oncology, UC Irvine Health, discusses emerging treatment strategies in the treatment of patients with cervical cancer.

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the presence of PIK3CA mutations and ESR1 mutations in patients with breast cancer enrolled in the phase III MONARCH 2 trial.

Niels Reinmuth, MD, PhD, leader of the Thoracic Oncology Department, Asklepios Lung Clinic, discusses ongoing studies looking at resistance to EGFR TKIs in patients with EGFR-positive non–small cell lung cancer.

Tony Mok, MD, professor, Department of Clinical Oncology, Chinese University of Hong Kong, discusses updated data with pembrolizumab in patients with non–small cell lung cancer.

Marina Chiara Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses patient reported outcomes with durvalumab by PD-L1 expression in patients with stage III unresectable non–small cell lung cancer.

Kim A. Reiss Binder, MD, assistant professor of medicine in the Division of Hematology Oncology at the University of Pennsylvania, discusses data on maintenance therapy with rucaparib (Rubraca) in patients with pancreatic cancer.

Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.

Sarah Ferguson, MD, FRCSC, associate professor of gynecologic oncology, University of Toronto, Princess Margaret Cancer Centre, discusses treatment options for patients with early-stage cervical cancer.

Neil P. Shah, MD, PhD, professor of medicine, Division of Hematology and Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses TKI treatment discontinuation in patients with chronic myeloid leukemia.

Eric Jonasch, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the use of single-agent pembrolizumab in the treatment of patients with metastatic non–clear cell renal cell carcinoma.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field.

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the impact of osimertinib (Tagrisso) in both clinical trial and real-world settings.

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of personalized care in patients with metastatic colorectal cancer.

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses treatment options available for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of durvalumab in the treatment of patients with gastric cancer.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.

Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).

Paul G. Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School, discusses treatment approaches targeting mutational burden in multiple myeloma.

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses standard treatment approaches available for patients with stage III non–small cell lung cancer (NSCLC).

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the role of liquid biopsies in colorectal cancer.

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the future of mantle cell lymphoma treatment.